Equities analysts expect that FibroGen Inc (NASDAQ:FGEN) will report earnings of ($0.39) per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have made estimates for FibroGen’s earnings, with estimates ranging from ($0.82) to $0.03. FibroGen reported earnings per share of $0.23 during the same quarter last year, which indicates a negative year-over-year growth rate of 269.6%. The business is scheduled to announce its next earnings results on Wednesday, February 26th.
According to Zacks, analysts expect that FibroGen will report full year earnings of ($0.16) per share for the current year, with EPS estimates ranging from ($0.57) to $0.28. For the next fiscal year, analysts forecast that the company will report earnings of ($0.56) per share, with EPS estimates ranging from ($1.76) to $1.43. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for FibroGen.
FibroGen (NASDAQ:FGEN) last released its earnings results on Monday, November 11th. The biopharmaceutical company reported ($0.57) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.59) by $0.02. The business had revenue of $33.17 million for the quarter, compared to analysts’ expectations of $31.61 million. FibroGen had a return on equity of 7.33% and a net margin of 11.81%. The firm’s revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.50) earnings per share.
FGEN traded up $0.78 during trading on Thursday, reaching $37.65. The stock had a trading volume of 677,400 shares, compared to its average volume of 736,414. The stock has a market cap of $3.23 billion, a PE ratio of -36.55 and a beta of 1.84. The company has a debt-to-equity ratio of 0.07, a quick ratio of 8.95 and a current ratio of 9.01. FibroGen has a one year low of $32.33 and a one year high of $61.23. The business has a 50-day moving average of $38.25 and a 200-day moving average of $41.47.
In other FibroGen news, SVP Christine Chung sold 11,250 shares of the company’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $43.17, for a total transaction of $485,662.50. Following the completion of the sale, the senior vice president now directly owns 157,195 shares in the company, valued at $6,786,108.15. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Thomas B. Neff sold 39,636 shares of the company’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $44.33, for a total transaction of $1,757,063.88. Following the sale, the chief executive officer now owns 2,356,578 shares of the company’s stock, valued at $104,467,102.74. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 92,381 shares of company stock valued at $3,839,495. Company insiders own 7.83% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its position in FibroGen by 0.8% during the second quarter. Vanguard Group Inc. now owns 7,277,118 shares of the biopharmaceutical company’s stock valued at $328,780,000 after buying an additional 56,378 shares during the period. BlackRock Inc. boosted its holdings in shares of FibroGen by 1.0% during the second quarter. BlackRock Inc. now owns 6,233,136 shares of the biopharmaceutical company’s stock worth $281,613,000 after purchasing an additional 60,249 shares during the period. Hillhouse Capital Advisors LTD. boosted its holdings in shares of FibroGen by 36.0% during the second quarter. Hillhouse Capital Advisors LTD. now owns 2,724,519 shares of the biopharmaceutical company’s stock worth $123,094,000 after purchasing an additional 721,232 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of FibroGen by 13.2% during the second quarter. Janus Henderson Group PLC now owns 2,500,567 shares of the biopharmaceutical company’s stock worth $112,976,000 after purchasing an additional 291,808 shares during the period. Finally, First Trust Advisors LP boosted its holdings in shares of FibroGen by 7.7% during the second quarter. First Trust Advisors LP now owns 2,046,192 shares of the biopharmaceutical company’s stock worth $92,447,000 after purchasing an additional 145,732 shares during the period. Institutional investors and hedge funds own 69.71% of the company’s stock.
FibroGen Company Profile
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Story: 52-Week High/Low
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.